Keyword: amyloid beta

Eisai and Biogen’s BACE inhibitor reduced amyloid beta levels in Alzheimer’s patients, but it failed to slow symptom decline versus placebo.

EIP Pharma is enrolling a phase 2b trial of neflamapimod, which targets synaptic dysfunction.

Eli Lilly has made the painful decision to abandon solanezumab for early-stage Alzheimer's after its much-anticipated EXPEDITION3 trial bombs.

The plaque-forming protein amyloid has been implicated in diseases ranging from Alzheimer’s to cataracts. Now scientists at the Flanders Institute for Biotechnology in Belgium are perfecting a way to harness the protein and turn it into something good: a potential treatment for cancer. 

NeuroPhage Pharmaceuticals hopes to reinvent itself a bit with a new name, Proclara Biosciences, and a cash infusion of $47 million.